Myrelez (Lanreotide Acetate)

Lanreotide acetate mimics natural somatostatin, binding to somatostatin receptors (mainly sst2 and sst5). This binding blocks adenylate cyclase activity, lowers cAMP levels, and suppresses the secretion of growth hormone, insulin‑like growth factor‑1, and various gastrointestinal hormones, thereby reducing tumor growth and hormone‑mediated effects.

The dosage of Myrelez is individualized. A qualified prescriber determines the appropriate dose, injection interval, and treatment duration based on the patient’s specific condition, response, and clinical guidelines.

Safety data for lanreotide acetate in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the Myrelez product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Myrelez (lanreotide) and other analogues such as octreotide share a similar mechanism of receptor activation but differ in formulation and dosing frequency. Lanreotide is typically administered as a long‑acting depot injection every 4–8 weeks, offering less frequent dosing compared with some short‑acting alternatives.

Myrelez should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial before use.

Myrelez is given by subcutaneous injection, usually into the abdomen or thigh. The injection is performed by a healthcare professional or a trained patient following aseptic technique and the prescriber’s instructions.

Serious risks include gallstone formation, hyperglycemia or new‑onset diabetes, acute pancreatitis, and severe allergic reactions such as anaphylaxis. Patients should be monitored for these events and instructed to seek immediate medical attention if symptoms arise.

Myrelez is contraindicated in patients with known hypersensitivity to lanreotide acetate or any excipients in the formulation. Caution is advised for individuals with uncontrolled diabetes, active gallbladder disease, or severe hepatic impairment, and it should be avoided in pregnancy unless clearly needed.